Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
- 1 August 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (8), 3427-3431
- https://doi.org/10.1128/aac.01753-09
Abstract
CXA-101 is a novel, broad-spectrum cephalosporin with excellent antipseudomonal activity. A Phase 1 study was performed to determine the safety, tolerability, and pharmacokinetics of CXA-101 after single- and multiple-dose intravenous administration over 1 h to healthy male and female subjects. In part 1 of the study, five cohorts of eight subjects each (six receiving CXA-101 and two receiving a placebo) received single ascending doses of 250, 500, 1,000, 1,500, and 2,000 mg. In part 2, cohorts 1 and 2 received 500 mg and 1,000 mg, respectively, every 8 h, and cohort 3 received 1,500 mg every 12 h; each cohort received dosing for 10 days. Standard safety and tolerability assessments were performed. Blood and urine pharmacokinetic samples were assayed by a validated bioanalytical method and analyzed using standard noncompartmental methodology. All 64 subjects completed dosing; none withdrew from the study. Drug-related systemic adverse events were infrequent and mild. Mild, non-treatment-limiting infusion site events occurred during multiple-dose administration. No clinically significant laboratory or electrocardiographic finding or dose-limiting toxicity was observed. CXA-101 exhibited dose-linear pharmacokinetics; the mean plasma half-life was ∼2.3 h. More than 90% of the administered dose was eliminated unchanged through renal excretion. In summary, CXA-101 administered as a 1-hour infusion was generally safe and well tolerated in single doses up to 2,000 mg and in multiple doses up to 3 g daily over 10 days. The favorable safety and predictable pharmacokinetic profile of CXA-101 support its continuing clinical development for the treatment of serious bacterial infections.Keywords
This publication has 10 references indexed in Scilit:
- Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit PatientsAntimicrobial Agents and Chemotherapy, 2010
- Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical StrainsAntimicrobial Agents and Chemotherapy, 2010
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPEThe Journal of Infectious Diseases, 2008
- What is in the pipeline for Gram-negative pathogens?Expert Review of Anti-infective Therapy, 2008
- The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combinationExpert Review of Anti-infective Therapy, 2007
- Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?International Journal of Antimicrobial Agents, 2007
- The β-lactamase threat in Enterobacteriaceae, Pseudomonas and AcinetobacterTrends in Microbiology, 2006
- Trends in Antimicrobial Drug Development: Implications for the FutureClinical Infectious Diseases, 2004